Posted by Michael Wonder on 25 Sep 2018
European Commission approves Imfinzi for locally-advanced, unresectable NSCLC
24 September 2018 - Phase III PACIFIC trial demonstrated compelling overall survival benefit and progression-free survival of more than 11 months.
AstraZeneca and MedImmune today announced that the European Commission has granted marketing authorisation for Imfinzi (durvalumab) as monotherapy for the treatment of locally-advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on ≥1% of tumour cells and whose disease has not progressed following platinum-based chemotherapy and radiation therapy.
The approval is based on results from the Phase III PACIFIC trial.
